NCT05442554 - A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions

T-Cell Lymphoma

Interventions

DRUG

Brentuximab vedotin

Brentuximab vedotin IV infusion.

Trial Locations (4)

Peking University First Hospital, Beijing

Peking University Third Hospital, Beijing

Huashan Hospital, Fudan University, Shanghai

West China Hospital, Sichuan University, Chengdu